INKT / MiNK Therapeutics Undervalued Given Potential Of Platform

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discove more_horizontal

NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery more_horizontal

NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery more_horizontal

MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Zack Armen – Head-Investor Rela more_horizontal

After losing some value lately, a hammer chart pattern has been formed for MiNK Therapeutics, Inc. (INKT), indicating that the stock has found support more_horizontal

AgenT-797 data presented at SITC in November was encouraging. More AgenT-797 cancer data expected at AACR on April 18. more_horizontal

MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q4 2022 Results Conference Call March 21, 2023 8:30 AM ET Company Participants Zack Armen - Head of Investor Re more_horizontal

NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, more_horizontal